Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody Persistence and Booster Response of MenABCWY and Bexsero in Adolescents
NCT02946385Phase 2Completed
- Sponsor
- GSK
- Start
- Nov 2016
- Primary completion
- Feb 2018
- Modality
- Fragment-Derived Small Molecules, Vaccines & Immunotherapeutics, Allosteric Modulators
- Countries
- 2
01
Overview
Phase 2, randomised, open-label trial of pexidartinib and recombinant neisseria meningitidis group B nhba fusion protein in meningococcal infection (6 arms), sponsored by GSK. Primary endpoints: Percentages of Subjects With hSBA Titers ≥LLOQ and hSBA Geometric Mean Titers. Started Nov 2016; status: completed.
02
Drugs
pexidartinibrecombinant neisseria meningitidis group B nhba fusion protein
03
Conditions
meningococcal infection
Beyond the preview
Go deeper on NCT02946385.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02946385.